Form 4 for RCUS Arcus Biosciences, Inc.
Accepted 2025-01-27 00:00:00 ET · period of report 2025-01-23 · accession 0001724521-25-000020 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-01-27 | 2025-01-23 | RCUS | ROSEN TERRY J | CEO, Dir | A - Grant | $0.00 | +165.0K | 2.53M | +7% | $0 |
| D | 2025-01-27 | 2025-01-23 | RCUS | ROSEN TERRY J | CEO, Dir | A - Grant | $0.00 | +650.0K | 650.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-01-23 | A | A | 165,000 | $0.00 | 2,534,360 | D | — | — | (F1) Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2025, subject to the Reporting Person's continued service to the Company. |
| 2 | Derivative | Stock Option (right to buy) | 2025-01-23 | A | A | 650,000 | $0.00 | 650,000 | D | $13.33 · — to 2035-01-22 | 650,000 Common Stock | (F2) The option becomes exercisable in 48 equal monthly installments after January 1, 2025, subject to the Reporting Person's continued service to the Company. |